Jm Goldman

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era
    Tariq I Mughal
    Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Front Biosci 11:209-20. 2006
  2. ncbi request reprint Is imatinib still an acceptable first-line treatment for CML in chronic phase?
    John M Goldman
    Department of Haematology, Imperial College London, United Kingdom
    Oncology (Williston Park) 26:901-7. 2012
  3. doi request reprint Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007
    Jm Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Bone Marrow Transplant 42:S11-S13. 2008
  4. doi request reprint BCR-ABL in chronic myelogenous leukemia--how does it work?
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Acta Haematol 119:212-7. 2008
  5. doi request reprint Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
    J M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London W12 0NN, UK
    Leukemia 23:1708-15. 2009
  6. doi request reprint Treatment strategies for CML
    John M Goldman
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, UK
    Best Pract Res Clin Haematol 22:303-13. 2009
  7. ncbi request reprint How I treat chronic myeloid leukemia in the imatinib era
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 110:2828-37. 2007
  8. ncbi request reprint Chronic myeloid leukemia--advances in biology and new approaches to treatment
    John M Goldman
    Department of Haematology, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
    N Engl J Med 349:1451-64. 2003
  9. ncbi request reprint Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era
    John Goldman
    Imperial College London at Hammersmith Hospital, London, UK
    Curr Opin Hematol 12:33-9. 2005
  10. ncbi request reprint Chronic myeloid leukemia-still a few questions
    John M Goldman
    Imperial College London, England, London, UK
    Exp Hematol 32:2-10. 2004

Detail Information

Publications80

  1. ncbi request reprint Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era
    Tariq I Mughal
    Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Front Biosci 11:209-20. 2006
    ..This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib...
  2. ncbi request reprint Is imatinib still an acceptable first-line treatment for CML in chronic phase?
    John M Goldman
    Department of Haematology, Imperial College London, United Kingdom
    Oncology (Williston Park) 26:901-7. 2012
    ..This choice may be based primarily on considerations of cost or possible side effects...
  3. doi request reprint Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007
    Jm Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Bone Marrow Transplant 42:S11-S13. 2008
    ....
  4. doi request reprint BCR-ABL in chronic myelogenous leukemia--how does it work?
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Acta Haematol 119:212-7. 2008
    ....
  5. doi request reprint Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
    J M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London W12 0NN, UK
    Leukemia 23:1708-15. 2009
    ....
  6. doi request reprint Treatment strategies for CML
    John M Goldman
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, UK
    Best Pract Res Clin Haematol 22:303-13. 2009
    ..For the minority of patients who are judged to have failed initial treatment with imatinib at standard dosage or increased dosage, the use of second-generation TKI or allogeneic stem cell transplantation must be considered...
  7. ncbi request reprint How I treat chronic myeloid leukemia in the imatinib era
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 110:2828-37. 2007
    ....
  8. ncbi request reprint Chronic myeloid leukemia--advances in biology and new approaches to treatment
    John M Goldman
    Department of Haematology, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
    N Engl J Med 349:1451-64. 2003
  9. ncbi request reprint Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era
    John Goldman
    Imperial College London at Hammersmith Hospital, London, UK
    Curr Opin Hematol 12:33-9. 2005
    ....
  10. ncbi request reprint Chronic myeloid leukemia-still a few questions
    John M Goldman
    Imperial College London, England, London, UK
    Exp Hematol 32:2-10. 2004
    ....
  11. doi request reprint Chronic myeloid leukemia: a historical perspective
    John M Goldman
    Department of Haematology, Imperial College London, London, UK
    Semin Hematol 47:302-11. 2010
    ..The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase...
  12. ncbi request reprint In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom
    Blood 111:2378-81. 2008
    ....
  13. ncbi request reprint Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma
    Evangelos Terpos
    Department of Hematology, Faculty of Medicine Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Int J Cancer 106:455-7. 2003
    ..TRACP-5b has also proved to be very useful for monitoring antimyeloma treatment, which had no effect on OPG levels...
  14. doi request reprint Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:3358-63. 2008
    ..Here, we report our experience in treating patients at a single institution in a setting where all events were recorded...
  15. ncbi request reprint Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    David Marin
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom
    Cancer 103:1850-5. 2005
    ....
  16. ncbi request reprint Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
    David Marin
    Department of Haematology, Hammersmith Hospital, W12 0NN, London, UK
    Lancet 362:617-9. 2003
    ..64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis...
  17. doi request reprint Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:4806-13. 2008
    ..Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear...
  18. ncbi request reprint Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, London, England
    Blood 99:3861-2. 2002
    ..This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML...
  19. ncbi request reprint Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma
    Evangelos Terpos
    Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Br J Haematol 123:106-9. 2003
    ..021). This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival...
  20. ncbi request reprint Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
    David J Barnes
    Department of Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Cancer Res 65:8912-9. 2005
    ....
  21. ncbi request reprint Chronic myeloid leukemia: current status and controversies
    Tariq I Mughal
    Department of Haematology, Hammersmith Hospital at the Imperial College London, London, United Kingdom
    Oncology (Williston Park) 18:837-44, 847; discussion 847-50, 853-4. 2004
    ..The advent of imatinib has thus necessitated a fundamental reappraisal of the approach to the initial management of CML...
  22. ncbi request reprint Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, Du Cane Road, London, UK
    Br J Haematol 137:423-8. 2007
    ..There were no grade III or IV non-haematological adverse effects. Grade I fatigue, hypocalcaemia and fever were common side effects. No responses were demonstrated after 6 months on the combination...
  23. ncbi request reprint Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
    Evangelos Terpos
    Department of Hematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, United Kingdom
    Blood 102:1064-9. 2003
    ....
  24. ncbi request reprint Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
    Sarah Marktel
    Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Haematologica 88:260-7. 2003
    ....
  25. pmc Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
    Haematologica 95:224-31. 2010
    ..However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors...
  26. doi request reprint European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
    ..The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response."..
  27. pmc Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
    Hugues de Lavallade
    Department of Haematology, Imperial College, Hammersmith Campus, 4th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK
    Haematologica 96:307-14. 2011
    ..The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies...
  28. doi request reprint Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
    ..05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR...
  29. ncbi request reprint Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
    Alex J Tipping
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK
    Exp Hematol 31:1073-80. 2003
    ..However, in a proportion of patients neither mechanism operates, and resistance appears to be a priori, existing prior to exposure to the drug. These mechanisms of imatinib resistance are poorly understood and may be heterogeneous...
  30. ncbi request reprint The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, ICSM, London, UK
    Br J Haematol 118:762-70. 2002
    ..01). Out of 155 patients refractory to IFN pre SCT, 70% achieved a cytogenetic response post SCT, which was complete or major in 31%. IFN refractory patients who sustained a CCR or MCR for 1-2 years after SCT had an excellent outcome...
  31. ncbi request reprint Management decisions in chronic myeloid leukemia
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Semin Hematol 40:97-103. 2003
    ..Undoubtedly, the suggestions made here will require revision as we acquire further information on the utility of imatinib...
  32. pmc Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
    Jaspal Kaeda
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Blood 107:4171-6. 2006
    ....
  33. ncbi request reprint Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism
    Beate Schultheis
    Department of Haematology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, United Kingdom
    Blood 99:1766-75. 2002
    ..Overall, the results suggest that SOCS-2 is a component of a negative feedback mechanism; it is induced by Bcr-Abl but cannot reverse its overall growth-promoting effects in blastic transformation...
  34. ncbi request reprint Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma
    Evangelos Terpos
    Department of Haematology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Eur J Haematol 70:34-42. 2003
    ..This is the first randomised trial to compare the efficacy of pamidronate and ibandronate, a third-generation aminobisphosphonate, in bone turnover and disease activity in MM patients...
  35. doi request reprint Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 115:4018-20. 2010
    ..CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib...
  36. pmc Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase
    John M Goldman
    Imperial College at Hammersmith Hospital, London, United Kingdom
    J Clin Oncol 28:1888-95. 2010
    ....
  37. ncbi request reprint Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia
    Jyoti Wadhwa
    Department of Haematology, Hammersmith Hospital and Faculty of Medicine, Imperial College at Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    Blood 99:2304-9. 2002
    ..We conclude that survival after onset of BT has improved in recent years but is still unsatisfactory. We speculate that the combined use of STI571 with cytotoxic drugs may offer additional benefit...
  38. ncbi request reprint Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons
    Myrtle Y Gordon
    Leukaemia Research Fund Centre, Imperial College Faculty of Medicine, Hammersmith Campus, London, UK
    Br J Haematol 122:424-9. 2003
    ..01 and 0.03 respectively). We conclude that heterogeneity in the CML patient population is analogous to the constitutional diversity in normal subjects...
  39. ncbi request reprint Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
    Eduardo Olavarria
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Blood 110:4614-7. 2007
    ....
  40. ncbi request reprint Clinical decisions for chronic myeloid leukemia in the imatinib era
    John M Goldman
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK
    Semin Hematol 40:98-103; discussion 104-13. 2003
    ..It is likely that the role of imatinib, used alone or in combination with other agents, will be more clearly defined in the near future...
  41. ncbi request reprint Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase
    John M Goldman
    Department of Haematology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK
    Semin Hematol 40:10-7. 2003
    ..This article reviews evidence for the safety and efficacy of imatinib and allogeneic stem cell transplantation and suggests strategic approaches to treatment in the new era of tyrosine kinase inhibition...
  42. ncbi request reprint Treatment of chronic myeloid leukaemia: lessons and challenges
    John M Goldman
    Imperial College at Hammersmith Hospital, London, UK
    Int J Hematol 76:189-92. 2002
    ..Further experience with the use of imatinib as a single agent or in combination with other anti-leukemic agents may alter the picture in the near future...
  43. ncbi request reprint Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia
    Stephen B Marley
    Leukaemia Research Fund Centre for Adult Leukaemia, Department of Haematology, Imperial College School of Medicine, London, UK
    Br J Haematol 116:162-5. 2002
    ..Thus, STI571 + FTI, STI571 + AG490 and IFN-alpha + ATRA may be better combination therapies for CML than STI571 + IFN-alpha, IFN-alpha + Ara-C or STI571 + AG490 + FTI...
  44. ncbi request reprint Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Jane F Apperley
    Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    N Engl J Med 347:481-7. 2002
    ..The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clinical efficacy in BCR-ABL-positive chronic myeloid leukemia...
  45. ncbi request reprint Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia
    Jaspal Kaeda
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Acta Haematol 107:64-75. 2002
    ....
  46. ncbi request reprint IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation
    William J Jordan
    Department of Immunology, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    Blood 103:717-24. 2004
    ..The data challenge the notion that aGVHD is purely a Th1-type cytokine-driven response, high-lighting a novel and highly significant link between the Th2-type cytokine IL-13 and aGVHD...
  47. doi request reprint Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia
    Mohamad Mohty
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 112:2163-6. 2008
    ..3-6.4; P = .011), suggesting that BMI-1 measured prior to allo-SCT can serve as a biomarker for predicting outcome in patients with CP-CML receiving allo-SCT, and may thus contribute to better therapeutic decisions...
  48. ncbi request reprint A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics
    Faris Q B Alenzi
    LRF Centre for Adult Leukaemia, Department of Haematology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Campus, DuCane Road, London W12 0NN, UK
    Exp Hematol 30:1428-35. 2002
    ..015 and 0.04, respectively).Fas, FasL, and caspase activation may play an important role in regulating myeloid progenitor cell kinetics...
  49. ncbi request reprint Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
    Agnes S M Yong
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    Blood 107:205-12. 2006
    ....
  50. ncbi request reprint Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients
    Liquan Gao
    Department of Immunology and Haematology, Imperial College of Science Technology and Medicine, Faculty of Medicine, Hammersmith Hospital, London
    Transplantation 75:1429-36. 2003
    ..This supports the use of CTL with this specificity for treatment of leukemia patients undergoing stem-cell transplantation...
  51. ncbi request reprint ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
    Robert P Hasserjian
    Dept of Pathology, Baystate Medical Center, Springfield, MA 01199, USA
    Am J Clin Pathol 117:360-7. 2002
    ..Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis...
  52. ncbi request reprint Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  53. ncbi request reprint Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
    Valeria A S De Melo
    Blood 110:3086-7. 2007
  54. ncbi request reprint Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571
    Pia Raanani
    The Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Clin Oncol 20:869-70. 2002
  55. ncbi request reprint MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
    Francois Xavier Mahon
    Laboratoire Greffe de Moelle, Universite Victor Segalen, Bordeaux, France
    Blood 101:2368-73. 2003
    ..The possible role of MDR overexpression in clinical resistance to imatinib remains to be defined. We therefore confirm that imatinib should be added to the extensive list of drugs that can be affected by the MDR phenomenon...
  56. ncbi request reprint Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    Charles L Sawyers
    Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Blood 99:3530-9. 2002
    ..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
  57. ncbi request reprint Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate
    David Marin
    Haematologica 88:227-9. 2003
  58. ncbi request reprint A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
    Oliver G Ottmann
    Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Blood 100:1965-71. 2002
    ..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib...
  59. ncbi request reprint Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571
    Christophe Barthe
    Laboratoire de Greffe de Moelle et Laboratoire d hématologie, Université Victor Segalen and Service des Maladies du Sang, CHU de Bordeaux, Bordeaux, France
    Br J Haematol 119:109-11. 2002
    ..We suggest that the acquisition of point-mutations in the tyrosine kinase domain of Bcr-Abl may cause progressive clinical resistance to STI571...
  60. ncbi request reprint Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses
    David Marin
    Blood 102:2702-3; author reply 2703-4. 2003
  61. ncbi request reprint Advances in CML
    John M Goldman
    Hematology Branch, Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Clin Adv Hematol Oncol 5:270-2, 292. 2007
  62. ncbi request reprint Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?
    Tariq I Mughal
    Division of Hematology and Oncology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Front Biosci 11:198-208. 2006
    ..Here we review what is known of the mechanisms underlying the evolution of chronic myeloid leukemia from a chronic phase to a blast transformation...
  63. ncbi request reprint Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome
    Zi Xing Chen
    Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, Suzhou 215006, China
    Chin Med J (Engl) 117:968-71. 2004
    ....
  64. pmc Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    Timothy Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 108:28-37. 2006
    ..We recognize that our recommendations are provisional and will require revision as new evidence emerges...
  65. ncbi request reprint Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
    Marianna David
    Department of Haematology, University of Pecs, Pecs, Hungary
    Blood 109:61-4. 2007
    ..Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs...
  66. ncbi request reprint Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele
    Mona Anand
    Blood 108:2881-2. 2006
  67. ncbi request reprint The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
    Michael W N Deininger
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA
    Cancer 110:1509-19. 2007
    ..In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells...
  68. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  69. ncbi request reprint Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia
    Tariq I Mughal
    Clin Med 6:526-8. 2006
  70. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
    ..Most patients now receive a trial of imatinib before proceeding to HCT...
  71. ncbi request reprint Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Tim P Hughes
    Institute of Medical and Veterinary Science, Adelaide, SA, Australia
    N Engl J Med 349:1423-32. 2003
    ..We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission...
  72. ncbi request reprint Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007
    Tariq Mughal
    Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Clin Lymphoma Myeloma 7:S95-101. 2007
    ..At this time, children and younger adults should probably be considered for transplantation as first-line treatment...
  73. ncbi request reprint Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia
    Tariq I Mughal
    Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical School, Dallas 75390, USA
    Clin Lymphoma Myeloma 7:S81-4. 2007
    ..Herein, we discuss the emerging strategies for circumventing resistance associated with the Bcr-Abl T315I mutation...
  74. ncbi request reprint The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations
    David Marin
    Haematologica 87:979-88. 2002
    ..It is also active in the management of patients in advanced phases of CML...
  75. pmc High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
    Agnes S M Yong
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 110:770-5. 2007
    ..The presence of a donor immune response against PR1 may be advantageous and could be exploited therapeutically...
  76. doi request reprint Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
    Hugues de Lavallade
    Br J Haematol 141:745-7. 2008
  77. ncbi request reprint Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
    Moshe Talpaz
    M D Anderson Cancer Center, Houston, Texas, USA
    Blood 99:1928-37. 2002
    ..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity...
  78. ncbi request reprint International standardisation of quantitative real-time RT-PCR for BCR-ABL
    Nicholas C P Cross
    Leuk Res 32:505-6. 2008
  79. ncbi request reprint Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions
    Francesco Dazzi
    Blood 100:2673-4. 2002